| Abstrakt: |
A recent study conducted at Aarhus University Hospital compared the cardiovascular effectiveness of two drugs, empagliflozin and dapagliflozin, in adults with treated type 2 diabetes. The study used Danish health registries to emulate a hypothetical trial and found that there were no significant differences in cardiovascular outcomes between the two drugs over a six-year period. This research provides valuable information for healthcare professionals and patients in making informed decisions about treatment options for type 2 diabetes. [Extracted from the article] |
